Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes

Rayman, G.; Profozič, Velimir; Middle, M. V.

doi:10.1016/j.diabres.2006.09.006

Cited by 32 publications

(26 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27 Similar percentages of patients (glulisine 47.1% vs regular 48.5%) reached goal A1C of less than 7%. Subjects receiving glulisine had significantly lower self-reported 2-hour postprandial glucose levels (p = 0.0010) that were confirmed through preprandial (p = 0.0488) and postprandial (p = 0.0010) clinic testing.…”

Section: Study 3005mentioning

confidence: 78%

See 1 more Smart Citation

Insulin Glulisine: An Evaluation of Its Pharmacodynamic Properties and Clinical Application

Helms

Kelley

2009

Ann Pharmacother

View full text Add to dashboard Cite

Insulin glulisine is a safe and effective rapid-acting insulin analog for the treatment of adults with diabetes. Clinical benefit over other short- and rapid-acting insulin products is not established. Addition of insulin glulisine to a formulary should be based on institution-specific availability and cost differences between glulisine, lispro, and aspart in the absence of superiority of clinical efficacy or safety and data beyond 26 weeks.

show abstract

Section: Study 3005mentioning

confidence: 78%

“…Of the 2408 patients who received glulisine in Phase 3 clinical trials, 6.1% (147) were greater than 65 years of age and 1.12% (27) were greater than age 75 years. 10 A majority of these patients had type 2 diabetes.…”

Section: Geriatricsmentioning

confidence: 99%

Insulin Glulisine: An Evaluation of Its Pharmacodynamic Properties and Clinical Application

Helms

Kelley

2009

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

“…The study was designed to show noninferiority of glulisine to lispro in terms of A1c change from baseline to endpoint with a prespecified noninferiority margin of 0.4%. The same margin was used in glulisine Phase III studies in adult diabetes patients, 12,[18][19][20] as accepted by the European Medicines Agency and the Food and Drug Administration. To assess noninferiority, the twosided 95% confidence interval (CI) was computed for the adjusted mean difference between groups from an analysis of covariance model, with treatment, type of basal insulin at randomization, and (pooled) center as fixed effects, and baseline A1c as covariate.…”

Section: Discussionmentioning

confidence: 99%

Comparable Efficacy and Safety of Insulin Glulisine and Insulin Lispro When Given as Part of a Basal–Bolus Insulin Regimen in a 26-Week Trial in Pediatric Patients with Type 1 Diabetes

Philotheou

Arslanian²,

Blatniczky³

et al. 2011

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

Background: We compared the efficacy and safety of insulin glulisine with insulin lispro as part of a basal-bolus regimen in children and adolescents with type 1 diabetes. Methods: Overall, 572 children and adolescents (4-17 years old) using insulin glargine or neutral protamine Hagedorn insulin as basal insulin were enrolled in a 26-week, multicenter, open, centrally randomized, parallelgroup, noninferiority study. Subjects were randomized to receive glulisine (n ¼ 277) or lispro (n ¼ 295) 0-15 min premeal. Results: Baseline-to-endpoint hemoglobin A1c changes were similar between the two insulins: adjusted mean change (glulisine vs. lispro), 0.10% versus 0.16%; between-treatment difference (glulisine-lispro), &minsu;0.06, 95% confidence interval (À0.24; 0.12); and prespecified noninferiority margin, 0.4%. Overall, for all age groups together, the percentage of patients achieving American Diabetes Association age-specific A1c targets at endpoint was significantly higher (P ¼ 0.039) with glulisine (38.4%) versus lispro (32.0%). From Month 4 to endpoint, both ''all'' and ''severe'' symptomatic hypoglycemia rates were similar (3.10 vs. 2.91 and 0.06 vs. 0.07 events/ patient-month, respectively). Frequency and type of adverse events, serious adverse events, or hypoglycemia reported as serious adverse events were similar between both groups. Conclusions: Glulisine was as effective as lispro in baseline-to-endpoint A1c change, and both treatments were similarly well tolerated.

show abstract

“…To date, efficacy data on type 2 diabetes in the pediatric population have not been studied, but several trials have been performed in adults. [9][10][11] Additional searching was made by cross referencing original articles and reviews. Abstracts were screened from major meetings and the abstract included in this review was sourced from Diabetologica.…”

Section: Introductionmentioning

confidence: 99%

The role of insulin glulisine to improve glycemic control in children with diabetes mellitus

Carter¹,

Lih²,

Hibbert³

et al. 2010

DMSO

View full text Add to dashboard Cite

Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes

Cited by 32 publications

References 13 publications

Insulin Glulisine: An Evaluation of Its Pharmacodynamic Properties and Clinical Application

Insulin Glulisine: An Evaluation of Its Pharmacodynamic Properties and Clinical Application

Comparable Efficacy and Safety of Insulin Glulisine and Insulin Lispro When Given as Part of a Basal–Bolus Insulin Regimen in a 26-Week Trial in Pediatric Patients with Type 1 Diabetes

The role of insulin glulisine to improve glycemic control in children with diabetes mellitus

Contact Info

Product

Resources

About